



Advancing Patient Centered Care Through Shared Decision Making

montori.victor@mayo.edu
@vmontori

Victor M. Montori, MD, MSc
KER UNIT
Mayo Clinic

Disclosures



We do not draw funding
from for-profit
corporations.



What does
best look
like?

HbA1c < 7%

4 Statin Benefit Groups

- Clinical ASCVD*
- LDL-C ≥ 190 mg/dL, Age ≥ 21 years
- Primary prevention – Diabetes: Age 40-75 years, LDL-C 70-189 mg/dL
- Primary prevention - No Diabetes†: $\geq 7.5\%$ ‡ 10-year ASCVD risk, Age 40-75 years, LDL-C 70-189 mg/dL

*Atherosclerotic cardiovascular disease

†Requires risk discussion between clinician and patient before statin initiation

‡Statin therapy may be considered if risk decision is uncertain after use of ASCVD risk calculator



*Helping Cardiovascular Professionals
Learn. Advance. Heal.*





People
like
Maria Luisa



People
like
Maria Luisa


Biology

Maria Luisa \neq People like Maria Luisa

Context

Patient
values and
preference

Biology



Method to individualize care is shared decision making.






Shared Decision Making

A conversation in which patients and clinicians work out what to do

To form care that makes **intellectual**,
practical, and **emotional**
sense




2014 ACC/AHA Guidelines

CLASS I

1. In patients with AF, antithrombotic therapy should be individualized based on shared decision making after discussion of the absolute risks and RRs of stroke and bleeding and the patient's values and preferences. (*Level of Evidence: C*)

But how?



Which is best for me?

Different SDMs


Situations

Problems

Discussions

Interactions

Purposes



What matters?




What do we want?



How do we manage?

What to do?
Your input matters




Why are options discussed?

Why patient involvement matters?



**Choice
Awareness**




No technically correct answer

Best answer depends on
matters about which patients
have unique expertise

Avoid premature closure
(recommendation without or
before patient involvement)

Statin Choice

statindecisionaid.mayoclinic.org



Compared to usual care,
patients using the decision aid were
22 times more likely
to have an accurate sense of their baseline risk and
risk reduction with statins.

70% fewer statin Rx in low risk (<10%) group
3-fold increase in self-reported adherence

Summary of Mayo experience

Age: 40-95 (avg 65)

Primary care, ED, hospital, specialty care

Adds ~3 minutes to consultation



58% fidelity without training

Outcomes

74-90% clinicians want to use tools again

Effects on SDM are similar in vulnerable populations

Variable effect on clinical outcomes, cost



NOVEMBER 2014 check to see if

SUNDAY MONDAY TUESDAY WEDNESDAY

2

304, the Hospital higher ground

47BI CCC

5 Salvation Army started

Get copy of rent amount from silva started

9 call 601 at G.A. about rent

106 day com. Marcia 8:30

11 HCMC Rheumatology

Bring Nurse Robin in Sat 1PM

9 AM saw Marcel emerge

Sussannah AM

16

17 HCMC DT-1PM

18 HCMC CCC

19 Sunnah

SLP-KRC-1PM speech Lang 2pm

2PM mobic 7.5

in at 7:30 AM

pr. increasing today

23

10/24-24 off CCC 8pm

24 10/24-24 off

25 60 to 6K for

26 1PM DT

30

work

Speech Pathology 2PM Chang 5 PM Purple

Do-60! work 3:30 PM Speech

work Pathology

8AM CCC 1041 CCC

Pen-A

call to confirm Dr. Schesinger appointment tomorrow the 7th

THURSDAY

FRIDAY

SATURDAY

8 PM NA @ Sal. Army

612-321-3429

OCTOBER 2014

SMTWTFSS
1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31

NOVEMBER 2014

MTWTFSS
1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28 29
30

DECEMBER 2014

MTWTFSS
1 2 3 4 5 6
7 8 9 10 11 12 13
14 15 16 17 18 19 20
21 22 23 24 25 26 27
28 29 30 31

JANUARY 2015

SMTWTFSS
1 2 3
4 5 6 7 8 9 10
11 12 13 14 15 16 17
18 19 20 21 22 23 24
25 26 27 28 29 30 31

FEBRUARY 2015

SMTWTFSS
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28

call Marcel 601 Emerge

Pick-up at Trumador Park CVJ

Marshall

13 8:30 AM Disinfect

14 HCMC

15 Susannah

1 PM Emerge

1 PM Dr. bench

20-25-90 COST

10 AM Josh

Purple Build

10 AM

20 House Authority

21 House

22 6th

REVOLUTION ANNIVERSARY (MEX)

27 7 PM

28

29

worked worked

THANKSGIVING DAY (US)

Don't call relay just say I am done

75%

reported high and unsustainable
treatment burden


Spencer G. In prep
Tran et al. In prep

NONCOMPLIANCE



Purpose
Resilience
Literacy
Bandwidth
Health
Financial
Social
Environmental

Workload



Capacity

**Imbalance
workload
+
capacity**



Workload-capacity imbalance?

Treatment burden

Prioritize (SDM)
De-prescribe

Capacity



Capacity Coaching
Self management training

Palliative care
Mental health
Physical and occupational therapy

Financial and resource security services
Community and governmental resources

HbA1c

My clinical approach

Burden of illness: pain, fatigue, symptomatic hyper/hypo

Burden of treatment: workload + capacity

Promote health: diet, activity, stress

Estimate and reduce CVD risk

- Smoking
- Hypertension
- Statin (even high doses), aspirin
- GLP-1 agonists? Glucoretics?

Glycemic control: A1c target (nl-8%) + regimen

Failure: intensification vs. minimally disruptive care

Why not do everything to the patient?

For a patient at 30% at 10 years

Burden of treatment, cost to patient, and value to patient CV risk to take low dose statins >20%

20% Statin low dose reduce by 25% to 22.5% (-7.5)

Statin high dose reduce by 15% to 19.1% (-3.9)

Aspirin reduces risk by 15%* to 16% (-3)

Antihypertensive treatment by 20% to 13% (-3)

10% Glycemic control by 15% to 11% (-2)

Liraglutide by 13% to 9.6% (-1.4)

Empagliflozin by 14% to 8.3% (-1.3)

*ASCEND Trial, NEJM 379;16

Shared decision making is...



A human
expression of
kind and
careful care.

Careful and kind care

HD
Situation

Unhurried
Conversation

Sensible
resolution

CARE

A patient revolution for
careful and kind care

Why We
Revolt

Victor Montori



KER Unit Workshop

October 7-8, 2019

Mayo Clinic

Rochester, Minnesota

[CE.mayo.edu/carethatfits2019](https://ce.mayo.edu/carethatfits2019)



montori.victor@mayo.edu



[@vmontori](https://twitter.com/vmontori)



☒ 1 YEAR RISK
☐ 5 YEAR RISK

MEDICAL SITUATION

RISK OF STROKE

ISSUES

DOCUMENT

CHA2DS2-VASC 2

To begin, let's review your medical situation

Sex	<input checked="" type="button" value="M"/>	<input type="button" value="F"/>	Age	<input type="text" value="62"/>	<input type="button" value="i"/>
History of Hypertension	<input checked="" type="button" value="Yes"/>	<input type="button" value="No"/>			<input type="button" value="i"/>
Congestive Heart Failure	<input type="button" value="Yes"/>	<input checked="" type="button" value="No"/>			<input type="button" value="i"/>
Stroke / TIA / Thromboembolism	<input type="button" value="Yes"/>	<input checked="" type="button" value="No"/>			<input type="button" value="i"/>
History of Vascular Disease	<input type="button" value="Yes"/>	<input checked="" type="button" value="No"/>			<input type="button" value="i"/>
Diabetes Mellitus	<input checked="" type="button" value="Yes"/>	<input type="button" value="No"/>			<input type="button" value="i"/>

Continue



- 1 YEAR RISK
- 5 YEAR RISK

MEDICAL SITUATION

RISK OF STROKE

ISSUES

DOCUMENT

CHA2DS2-VASC 2

Over the next 5 years


88
people will have
no stroke

4
people will have
a fatal or
disabling stroke


8
people will have
a non-disabling
stroke

Current
Risk of Stroke
Without Anticoagulation

In 100 people like you who **are not**
taking an anticoagulant, **at 5 years...**



With Anticoagulation





Anticoagulation Choice

Decision Aid



- 1 YEAR RISK
- 5 YEAR RISK

MEDICAL SITUATION

RISK OF STROKE

ISSUES

DOCUMENT

CHA2DS2-VASC 2

Over the next 5 years


88
people will have no stroke

4
people will have a fatal or disabling stroke

8
people will have a non-disabling stroke

Current Risk of Stroke Without Anticoagulation

In 100 people like you who **are not** taking an anticoagulant, **at 5 years...**



Future Risk of Stroke With Anticoagulation

In 100 people like you who **are** taking an anticoagulant, **at 5 years...**



Over the next 5 years

93
people will have no stroke

2
people will have a fatal or disabling stroke

5
people will have a non-disabling stroke

5
people will avoid a stroke by taking anticoagulation



● 1 YEAR RISK
○ 5 YEAR RISK

MEDICAL SITUATION

RISK OF STROKE

ISSUES

DOCUMENT

CHA2DS2-VASC 2

Anticoagulation Choice

There are choices

To choose between
about how to

Bleeding

When taking an anticoagulant
you may...

- bruise more easily
- bleed more easily
- require emergency treatment

Risk of needing emergency treatment



Cost

Warfarin

Coumadin



\$545 per year
including cost of blood tests

Direct Anticoagulants



\$2,930 per year

Apixaban

Eliquis

Dabigatran

Pradaxa

Edoxaban

Savaysa

Rivaroxaban

Xarelto

Cost will depend on your insurance plan. Average
cost without insurance shown.



- ☒ 1 YEAR RISK
- ☐ 5 YEAR RISK

MEDICAL SITUATION

RISK OF STROKE

ISSUES

DOCUMENT

CHA2DS2-VASC 2

Fitting anticoagulation
in your life:

Which issue would you
like to discuss first?

- Bleeding
- Anticoagulation Routine
- Reversing Anticoagulation
- Cost
- Diet & Medication Interaction

Bleeding

In your day-to-day life...



Are there activities at work,
home, or during recreation where
you might fall or hurt yourself?

Exit

Discuss your medical risk factors



Anticoagulation Choice

Decision Aid



☒ 1 YEAR RISK
☐ 5 YEAR RISK

MEDICAL SITUATION

RISK OF STROKE

ISSUES

DOCUMENT

CHA2DS2-VASC 2

Fitting anticoagulation in your life:

Which issue would you like to discuss first?

- Bleeding
- Anticoagulation Routine
- Reversing Anticoagulation
- Cost
- Diet & Medication Interaction


Bleeding

In your medical situation...

Age	67	
Uncontrolled Hypertension	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	
Renal Disease	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	
Liver Disease	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	
History of Stroke	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	
Prior, or Predisposition to Bleeding	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	
Unstable or High INR	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	
Medication Predisposing Bleeding	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	
More than 8 Drinks per Week	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	

Exit

Average Risk





Anticoagulation Choice
Decision Aid



- ☒ 1 YEAR RISK
☐ 5 YEAR RISK

MEDICAL SITUATION

RISK OF STROKE

ISSUES

DOCUMENT

CHA2DS2-VASC 2
HAS-BLED 2

We have discussed that this patient has a 5-year risk of stroke associated with atrial fibrillation of **12%** and that this risk can be reduced with anticoagulation by **5% to 7%**.

We have discussed the pros and cons of the available options, including their impact on the risk of bleeding, cost, and practical considerations in using them regularly. After thorough discussion, we have decided to use **a Direct anticoagulant**

Intervention selected:



No Anticoagulation



Warfarin



Direct anticoagulant

Document Options:





































































Generate report



Copy to Clipboard

Document

New tools

 Diabetes Medication Choice Decision Aid								ES	EN
WHICH ISSUE WOULD YOU LIKE TO DISCUSS NEXT?		A1C ↓	DAILY ROUTINE	LOW BLOOD SUGAR	WEIGHT CHANGE	HEART BENEFITS	COSTS		
	Metformin 	1 - 2%				  			
	Insulin 					  			
	Pioglitazone 	1%				  			
	Liraglutide Exenatide 	0.5 - 1%				  			
	Sulfonylureas 	1 - 2%				  			
	Gliptins 	0.5 - 1%				  			
	SGLT2 Inhibitors 	0.5 - 1%				  			



Risk of Heart Attack :: Approaches :: Review Risk :: Decision


Current Risk of having a heart attack

In 100 people like you...

Over the next 10 years

82 people will
have no heart
attack

18 people will
have a heart
attack



There are two ways to reduce your risk

by changing:

- ☐ Way of Life
- ☐ Medicines

Select one to continue



Risk of Heart Attack :: Approaches :: Review Risk :: Decision


Current Risk
of having a heart attack

In 100 people like you...

Over the next 10 years


82 people will
have no heart
attack

18 people will
have a heart
attack



Future Risk
of heart attack

In 100 people like you...



Consider
Approaches?

☐ Way of Life

☒ Medicines

Over the next 10 years

88 people will
have no heart attack

12 people will
have a heart attack

Up to **6** people
will avoid a heart
attack by taking
medication



Risk of Heart Attack :: Approaches :: Review Risk :: Decision

Approaches

Are they right for you, can they work in your life?

	Lowering Risk	Daily Routine	Burdens	Other Benefits	Cost
✓ Physical Activity	+++	-	-	+	Equipment, gym fees ?
✓ Mediterranean Diet	+++	-	.	+	Additional food costs ?
✓ Stopping Smoking	+++	?	-	+	Stopping smoking medications, programs
✓ Omega 3 Supplements	.	.	-	+	Supplement costs
✓ Blood Pressure Medications	+++	-	-	?	Medication costs
✓ Diabetes Medications	++	-	-	?	Medication costs
✓ Statins	++	?	-	.	Medication costs
✓ Aspirin	+	?	-	.	Medication costs
Review Risk					



Anticoagulation Choice

Decision Aid

Medical Situation Risk of Stroke Anticoagulation Issues

CHA₂DS₂-VASC 4
HAS-BLED 1

Over the next year

4 people will have a fatal or disabling stroke

5 people will have a non-disabling stroke

91 people will have no stroke

Current Risk of Stroke without Anticoagulation

Future Risk of Stroke with Anticoagulation

Over the next year



Anticoagulation Choice

Decision Aid

- ☐ 1 Year Risk
☒ 5 Year Risk

Medical Situation Risk of Stroke Anticoagulation Issues

CHA₂DS₂-VASC 5

Fitting anti
in your life:
Which issue
like to disc



Anticoagulation Choice

Decision Aid

Risk of

Medical Situation Risk of Stroke Anticoagulation Issues

CHA₂DS₂-VASC 4
HAS-BLED 1

Anticoa
Rou

Work, Home & Fun
Activities

Cost

Anticoagulation Routine

Reve
Anticoa

Anticoagulation
Routine

The cost to you of each medication will depend on your insurance plan.

Warfarin requires committing to regular blood tests.

Co

Risk of Serious
Bleeding

The figures below provide a comparison of average costs without insurance.

There is no testing required with a Direct Anticoagulant.

Diet & M
Intera

Cost

Warfarin \$545 per year
Costs include the medication and blood tests.

Warfarin Once daily Regular blood tests
? Am I available to do the regular blood tests that Warfarin requires? Work / travel / family demands? Transportation?

Diet & Medication
Interactions

Direct Anticoagulants \$2,930 per year
Apixaban Eliquis
Dabigatran Pradaxa 110mg, 150mg
Edoxaban Lixiana
Rivaroxaban Xarelto

Direct Anticoagulants
Apixaban Eliquis AM PM
Dabigatran Pradaxa 110mg, 150mg AM PM
Edoxaban Lixiana Once daily
Rivaroxaban Xarelto Once daily

Agents that reduce CV risk

Pioglitazone (IRIS)*

Canaglifloxin (CANVAS)*

Empagliflozin (EMPA-REG)

Dapagliflozin (DECLARE-TIMI 58)

Liraglutide (LEADER)*

Semaglutide (SUSTAIN-6)

* Inconsistent results within the class

EMPA-REG

- RCT at low risk of bias (blinding)
- 7028 >5y DM2 (A1c 7-10%)+ CV
- Empagliflozin (10 or 25 mg) vs. Placebo
- At 2.5y: **14% RRR in CV** death, nonfatal MI, nonfatal stroke, from 12 % to 10.5%
- **Certainty:** Consistent with prior trials and CANVAS (cana), but not with DECLARE (dapa), a 17160-patient 4y trial: no effect on MACE/CV death

Empagliflozin (HbA1c 0.5%)

Participants with additional:	Placebo	Empagliflozin
Glucose-lowering medications added in concordance with an escalated 'standard of care'	31.5%	19.5%
Insulin	11.5%	5.8%
Dipeptidyl peptidase 4-inhibitor	8.3%	5.6%
Sulfonylurea	7.0%	3.8%
Thiazolidinedione	2.9%	1.2%

Concerns: change in protocol, posthoc outcomes, 40% deaths uncertain

N Engl J Med 2015;373:2117-28.

LEADER

Liraglutide (HbA1c 0.5%)

RCT at low risk of bias (blinding)

9340 DM2 (A1c 7-10%)+ 80% CV

Liraglutide (1.8 mg daily) vs. placebo

At 3.5y: **13% RRR** in CV death, nonfatal MI, nonfatal stroke from 15% to 13%

Concerns:

Differences between arms in diabetes treatments

Adverse effects in patients with advanced heart failure?

Class effect?

Exenatide weekly (EXSCEL, n=14752) Neg

Semaglutide weekly (SUSTAIN-6, n=3297)

Pos

Lixisenatide daily (ELIXA, n=6068 ACS)

Neg

N Engl J Med 2016;375:311-22.

